NASDAQ traded stock with a BIG short position.

From Huge Alerts | Ad

Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!

See how this NASDAQ Bio-tech is offering viable solutions

TVGN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 56.60%

Insider Buying (Last 12 Months): $2,460.00

Insider Selling (Last 12 Months): $1,747,332.00

Tevogen Bio Insider Trading History Chart

Tevogen Bio Share Price & Price History

^$1.72

▼ -0.24 (-12.24%)

As of 11/5/2024 01:00 AM ET

Days: 30 | 90 | 365

Banking failure dead ahead

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Tevogen Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/17/2024	Neal Flomenberg	Insider	Sell	1,078,600	$1.62	$1,747,332.00	4,254,302
6/12/2024	Kirti Desai	CFO	Buy	3,000	$0.82	$2,460.00	9,699,186

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

SEC Filings (Institutional Ownership Changes) for Tevogen Bio (NASDAQ:TVGN)

Tevogen Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company	Details
5/9/2024	Portland Global Advisors LLC	5,782,209	$21.68M	3.0%	N/A	36.550%

Data available starting January 2016

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Read More

Today's Range

Now: $1.72

$1.69

$2.07

50 Day Range

MA: $0.96

$0.26

$3.05

52 Week Range

Now: $1.72

$0.26

$21.09

Volume

4,799,797 shs

Average Volume

4,972,529 shs

Market Capitalization

$293.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Tevogen Bio?: Tevogen Bio's top insider investors include:
Kirti Desai (CFO)
Neal Flomenberg (Insider)
Learn More about top insider investors at Tevogen Bio.

NASDAQ traded stock with a BIG short position.

From Huge Alerts | Ad

Small cap NASDAQ firm is an innovative leader in non-opioid pain therapeutics. The company’s offerings could significantly aid in stopping the opioid crisis and create maximum shareholder growth!

See how this NASDAQ Bio-tech is offering viable solutions